Results 131 to 140 of about 4,513 (159)

The interaction of ifosfamide and aprepitant in gynecologic malignancies

, 2013
Mackenzie L. Shindorf, Kelly J. Manahan, John P. Geisler   +2 more
openalex   +1 more source

Efficacy and safety of 5 mg olanzapine combined with aprepitant, granisetron and dexamethasone to prevent carboplatin-induced nausea and vomiting in patients with gynecologic cancer: A multi-institution phase II study

, 2020
Hirotoshi Iihara, Mototsugu Shimokawa, Yoh Hayasaki, Yukiyoshi Fujita, Masakazu Abé, Motoki Takenaka, Senri Yamamoto, Takahiro Arai, Michiru Sakurai, Minako Mori, Kazuto Nakamura, Nobuhiro Kado, Saki Murase, Ryuichi Shimaoka, Akio Suzuki, Ken‐ichirou Morishige   +15 more
openalex   +1 more source

Cyclic Vomiting Syndrome Versus Cannabinoid Hyperemesis Syndrome. [PDF]

J Neurogastroenterol Motil
Singh B, Grover P, Kaur G.
europepmc   +1 more source

Emesis Rate and Rescue Medication Use in Children Using Aprepitant to Prevent Chemotherapy-Induced Nausea and Vomiting (Cinv)

, 2014
H.J. Kang, Susan Loftus, Amanda Taylor, Cara DiCristina, S. Green, C. Michel Zwaan   +5 more
openalex   +1 more source

Radiotherapy Plus the Neurokinin-1 Receptor Antagonist Aprepitant: A Potent Therapeutic Strategy for the Treatment of Diffuse Intrinsic Pontine Glioma. [PDF]

Cancers (Basel)
Muñoz M, Rosso M.
europepmc   +1 more source

PCN13 COST-EFFECTIVENESS ANALYSIS OF APREPITANT IN THE PREVENTION OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING IN PATIENTS RECEIVING EITHER CISPLATIN-BASED CHEMOTHERAPY REGIMENS OR MODERATELY EMETOGENIC CHEMOTHERAPY

, 2006
L Annemans, Daniëlle Strens, Erica Lox, Claire Petit, Hugues Malonne   +4 more
openalex   +1 more source

Olanzapine plus triple antiemetic therapy for prevention of carboplatin-induced nausea: a pooled analysis of two clinical trials. [PDF]

BMC Cancer
Kojima S, Inui N, Suzuki T, Tanaka K, Karayama M, Inoue Y, Yasui H, Hozumi H, Suzuki Y, Furuhashi K, Fujisawa T, Enomoto N, Nishimoto K, Matsuura S, Hashimoto D, Matsui T, Asada K, Suda T.   +17 more
europepmc   +1 more source

Physiologically based pharmacokinetic modeling supports investigation of potential drug-drug interactions in the pre- and early post-hematopoietic stem cell transplantation stages. [PDF]

Front Pharmacol
Wang P, Lu J, Yang J.
europepmc   +1 more source

Safety and antiemetic efficacy of weekly administration of netupitant/palonosetron plus dexamethasone during 5 weeks of concomitant chemo-radiotherapy-the DANGER-emesis study. [PDF]

Support Care Cancer
Detlefsen SS, Andersen DS, Knudsen AØ, Nøttrup TJ, Möller S, Nyvang GB, Jørgensen TL, Herrstedt J, Ruhlmann CH.   +8 more
europepmc   +1 more source

STOP-CINV Study: Safety and Efficacy of IV Akynzeo® (Fosnetupitant 235 mg and Palonosetron 0.25 mg) for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Indian Patients. [PDF]

Cureus
Shukla P, Valame S, Nanda S, Shakya NK, Verma AK, Hanji A, Pednekar A, Bhagat S, Patil S, Petare AU, Bhushan S, Barkate H.   +11 more
europepmc   +1 more source